Regina E.  Groves net worth and biography

Regina Groves Biography and Net Worth

Director of AtriCure
Regina E. Groves has served as one of our directors since March 2017. Ms. Groves currently serves as a director for two privately held medical device companies, Advanced NanoTherapies, Inc. and Stimwave LLC. Ms. Groves joined Stimwave’s Board of Directors in July 2019 and was the Chief Financial Officer and Chief Operating Officer from September 2019 to December 2020. From September 2015 to March 2019, Ms. Groves was the Chief Executive Officer at REVA Medical, Inc., a medical device company focused on the development and commercialization of bioresorbable polymer technologies for vascular applications. Prior to joining REVA Medical, Ms. Groves served as Vice President and General Manager of the AF Solutions, Cardiac Rhythm and Heart Failure division of Medtronic, Inc., a leading global medical technology company. In this position, she successfully developed and executed strategies to re-enter the catheter-based Afib ablation market and achieved the goal to be market leader in paroxysmal, or intermittent, Afib ablation. Additionally, Ms. Groves successfully acquired and integrated companies, completed numerous clinical trials and launched novel products in the United States and worldwide. Prior to this, she was the Vice President of Quality and Regulatory for Medtronic’s Cardiac Rhythm Disease Management (CRDM) business from 2006 to 2008 and before that was Vice President and General Manager for Patient Management CRDM at Medtronic from 2002 to 2006. Ms. Groves holds a B.S. in Pharmacy from the University of Florida and an M.B.A. from Harvard Graduate School of Business Administration. Ms. Groves has significant leadership experience and a diverse business skill set with a global perspective. She is an expert in enterprise risk assessment and mitigation and possesses functional experience in strategy, finance, sales, manufacturing operations, and marketing matters which the Board considers as valuable skills for evaluating and improving the Company’s competitive position. Ms. Groves qualifies as an “audit committee financial expert” under SEC rules.

What is Regina E. Groves' net worth?

The estimated net worth of Regina E. Groves is at least $410,220.00 as of May 26th, 2021. Ms. Groves owns 19,350 shares of AtriCure stock worth more than $410,220 as of June 19th. This net worth estimate does not reflect any other assets that Ms. Groves may own. Learn More about Regina E. Groves' net worth.

How do I contact Regina E. Groves?

The corporate mailing address for Ms. Groves and other AtriCure executives is 7555 INNOVATION WAY, MASON OH, 45040. AtriCure can also be reached via phone at (513) 755-4100 and via email at [email protected]. Learn More on Regina E. Groves' contact information.

Has Regina E. Groves been buying or selling shares of AtriCure?

Regina E. Groves has not been actively trading shares of AtriCure during the past quarter. Most recently, Regina E. Groves sold 4,208 shares of the business's stock in a transaction on Wednesday, May 26th. The shares were sold at an average price of $71.95, for a transaction totalling $302,765.60. Following the completion of the sale, the director now directly owns 19,350 shares of the company's stock, valued at $1,392,232.50. Learn More on Regina E. Groves' trading history.

Who are AtriCure's active insiders?

AtriCure's insider roster includes Tonya Austin (Insider), Mark Collar (Director), Vinayak Doraiswamy (Insider), Scott Drake (Director), Regina Groves (Director), David Grumhaus, Jr. (Portfolio Manager), Justin Noznesky (Insider), Salvatore Privitera (Insider), Douglas Seith (COO), Sven Wehrwein (Director), and Angela Wirick (CFO). Learn More on AtriCure's active insiders.

Are insiders buying or selling shares of AtriCure?

During the last year, AtriCure insiders bought shares 1 times. They purchased a total of 5,000 shares worth more than $111,250.00. During the last year, insiders at the medical device company sold shares 7 times. They sold a total of 19,281 shares worth more than $742,976.93. The most recent insider tranaction occured on May, 30th when insider Salvatore Privitera bought 5,000 shares worth more than $111,250.00. Insiders at AtriCure own 3.2% of the company. Learn More about insider trades at AtriCure.

Information on this page was last updated on 5/30/2024.

Regina E. Groves Insider Trading History at AtriCure

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
5/26/2021Sell4,208$71.95$302,765.6019,350View SEC Filing Icon  
4/30/2021Buy34$76.68$2,607.12View SEC Filing Icon  
9/14/2020Sell6,313$41.83$264,072.7921,809View SEC Filing Icon  
9/12/2019Buy500$24.86$12,430.0025,670View SEC Filing Icon  
3/1/2018Buy1,000$17.43$17,430.00View SEC Filing Icon  
See Full Table

Regina E. Groves Buying and Selling Activity at AtriCure

This chart shows Regina E Groves's buying and selling at AtriCure by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

AtriCure Company Overview

AtriCure logo
AtriCure, Inc. develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, Europe, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation, and ablate cardiac tissue with the same device; and the Coolrail device, which enables users to make longer linear lines of ablation. It also provides cryoICE Cryoablation System that enables the user to make linear ablations of varied lengths; EPi-Sense Systems, a single-use disposable device used for the treatment of symptomatic, drug-refractory, and long-standing persistent atrial fibrillation; cryoSPHERE probe, which provides temporary pain relief by applying cryothermic energy to targeted intercoastal peripheral nerves in the ribcage; AtriClip System, an implantable device coupled to a single-use disposable applier; and LARIAT System, a suture-based solution for soft-tissue closure. In addition, the company sells Lumitip dissectors to separate tissues to provide access to key anatomical structures that are targeted for ablation; Glidepath guides for placement of clamps; Subtle Cannula's to support access for EPi-Sense catheters; and various reusable cardiac surgery instruments. It markets and sells its products through independent distributors and direct sales personnel. The company was incorporated in 2000 and is headquartered in Mason, Ohio.
Read More

Today's Range

Now: $21.20
Low: $18.94
High: $23.26

50 Day Range

MA: $22.58
Low: $19.86
High: $25.90

2 Week Range

Now: $21.20
Low: $18.94
High: $59.61


3,498,011 shs

Average Volume

538,934 shs

Market Capitalization

$1.01 billion

P/E Ratio


Dividend Yield